Pharma

Kura and Kyowa Report Strong KOMZIFTI AML Data

Kura Oncology and Kyowa Kirin rolled out fresh data on KOMZIFTI ziftomenib paired with venetoclax and azacitidine. The numbers land well for both newly diagnosed and relapsed or refractory AML with NPM1 mutations or KMT2A rearrangements. The readout comes from the ongoing KOMET 007 Phase 1a/1b study and was presented today at ASH 2025. In newly diagnosed NPM1 mutated AML the triplet came in strong. Among 37 evaluable patients CRc hit 86 percent and complete responses landed at 73 percent. Most striking was that 68 percent of CRc responders cleared molecular MRD by central NGS. Median duration of response and overall survival have not even been reached yet. Two thirds of patients were still alive and either on treatment or in long term follow up at data cutoff. Safety tracked…